Strand Therapeutics began dosing the first patients with STX-003, a systemic programmable mRNA therapy designed for tumor-selective activation. The company positioned the program around localizing expression to reduce systemic toxicity risks associated with broadly delivered nucleic acid platforms. The update frames STX-003 as part of a broader clinical pipeline expansion that will require careful monitoring of expression targeting, dose exposure, and safety outcomes typical for mRNA constructs that depend on activation logic. Strand’s initiation in this stage also suggests investors’ and regulators’ continued interest in strategies that translate systemic delivery into controlled, tissue-restricted therapeutic activity. As dosing initiates, the next readouts will likely focus on tolerability, pharmacodynamics, and signal development in relevant tumor settings as the trial progresses.